Teva Pharmaceutical Industries Ltd. has taken a significant step toward transforming the pharmaceutical industry with the launch of Teva Rise, a global open innovation platform designed to tackle some of the sector's most pressing challenges through cutting-edge technologies.
Connecting Innovators with Real-World Pharma Challenges
Announced on November 19, 2025, Teva Rise represents the company's first-ever global innovation initiative aimed at accelerating patient impact and driving business transformation. The platform serves as a bridge between startups and technology companies worldwide and Teva's various business units, creating opportunities for co-creation and solution development.
The timing of this launch coincides with a pivotal moment for the pharmaceutical industry, as artificial intelligence and digital transformation continue to reshape drug development, manufacturing processes, and patient care delivery. By opening its doors to external innovators, Teva aims to accelerate the adoption of next-generation technologies while strengthening its position as a leading biopharmaceutical company.
Seven Critical Challenges for First Cohort
The inaugural Rise program features seven specific challenges across research and development, manufacturing and supply chain, and commercial operations. These carefully selected problems represent some of the most complex issues facing modern pharmaceutical companies.
In the R&D domain, Teva is seeking human-predictive platforms for testing biologics, including advanced technologies like organ-on-chip systems and sophisticated cell culture methods for preclinical drug development. The company is also looking for AI-powered protocol design tools that can simulate clinical trial outcomes, optimize parameters, and improve patient recruitment and retention.
On the patient care front, Teva aims to revolutionize the experience of long-acting injectable therapies through digital health tools, smart devices, or behavioral science solutions that monitor and support patient perception, ultimately improving treatment outcomes while reducing healthcare costs.
Manufacturing and Commercial Innovation Opportunities
The manufacturing challenges focus on asset reliability and predictive maintenance, calling for AI-powered models that integrate historical and real-time data to improve equipment reliability and uptime. Another manufacturing challenge involves product quality and risk prediction using AI and machine learning tools to provide predictive insights into product robustness and guide mitigation efforts.
Commercial operations present two additional challenges: tender value optimization through advanced analytics platforms and AI-driven decision support, and resource allocation intelligence using data-driven systems to enable optimal decision-making during supply chain disruptions or shortages.
This initiative aligns directly with Teva's Pivot to Growth strategy, demonstrating the company's commitment to embracing innovation across its entire ecosystem. The platform will enable startups and technology partners to validate their solutions in real-world settings while scaling their impact across Teva's global operations in the United States, Europe, Israel, and beyond.
Through this partnership model, Teva Rise represents a significant shift in how established pharmaceutical companies can leverage external innovation to address internal challenges while providing emerging technology companies with unprecedented access to industry expertise and scaling opportunities.
